川芎平喘合剂联合西药治疗慢性持续期支气管哮喘临床研究

目的评价川芎平喘合剂联合西医常规疗法治疗慢性持续期支气管哮喘的临床疗效和安全性。方法采用随机、开放、对照的研究方法 ,将101例轻至中度慢性持续期支气管哮喘患者分为治疗组（67例）和对照组（34例）。对照组采用西医常规治疗,治疗组在西医常规治疗基础上加服川芎平喘合剂。观察临床症状评分及肺通气功能相关指标最大呼气峰流速（PEF）占预计值%、1秒钟用力呼气容积（FEV1）占预计值%的变化,并进行哮喘控制测试,记录不良事件发生情况。结果治疗组第4周、第8周、第12周治疗后哮喘症状评分均较4周前下降（P〈0.01）,且均低于对照组同期（P〈0.01,P〈0.05）;治疗组第4周、第8周哮喘完全控制率均高于本组4周前及对照组同期（P〈0.05）;治疗组第4周、第8周的PEF占预计值%、FEV1占预计值%均较4周前上升（P〈0.01）,且治疗组第4周、第8周的PEF占预计值%、FEV1占预计值%及第12周的PEF占预计值%亦高于对照组（P〈0.01,P〈0.05）。结论川芎平喘合剂联合西医基础治疗能有效改善轻中度慢性持续期哮喘患者的临床症状及肺功能。

Clinical study on treatment of chronic persistent bronchial asthma by ＂Chuanxiong Antiasthma Mixture＂

Objective To evaluate the clinical efficacy and safety of ＂Chuanxiong Antiasthma Mixture＂ in treating chronic persistent bronchial asthma.Methods A total of 101 patients were enrolled and randomly divided into treatment group（n=67） and control group（n=34）.Asthma symptoms score,asthma control test（ACT）,peak expiratory flow（PEF） rate,forced expiratory volume in one second（FEV1） rate and adverse events were observed.Results Asthma symptoms scores in 4th week,8th week and 12th week in the treatment group were decreased in comparison with four weeks before（P〈0.01）,and also lower than those in the control group（P〈0.01,P〈0.05）.While the asthma control rates in 4th week and 8th week in the treatment group were increased in comparison with four weeks before（P〈0.01）,and higher than those in the control group（P〈0.05）.PEF rates and FEV1 rates in 4th week,8th week and PEF rate in 12th week in the treatment group were also increased in comparison with four weeks before（P〈0.01）,and higher than those in the control group（P〈0.01,P〈0.05）.Conclusion ＂Chuanxiong Antiasthma Mixture＂ can obviously improve airway ventilation of moderate-to-severe chronic persistent bronchial asthma.